Assessment of the efficacy of rosuvastatin in patient groups with a dissimilar risk profile in an observational study (HEROS) - HEROS

Study identifier:25V07

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Assessment of the efficacy of rosuvastatin in patient groups with a dissimilar risk profile in an observational study (HEROS)

Medical condition

Hypercholesterolemia

Phase

Healthy volunteers

Study drug

Rosuvastatin

Sex

All

Actual Enrollment

Study type

Observational

Age

18 Years - 75 Years

Date

Study Start Date: 01 May 2003

Primary Completion Date: -

Study Completion Date: 01 Apr 2005

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1 Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca	Drug: Rosuvastatin Oral Other Name: Crestor

Arms

Assigned Interventions

1
Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca

Drug: Rosuvastatin
Oral

Other Name: Crestor

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1154&filename=CSR-25V07.pdf
Download
CSR-25V07.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Netherlands Clinical Study Information

+31 79 363 2284

MIMCV.nl@astrazeneca.com

Investigators

Principal Investigator

Ingrid van Geel